September 12th 2025, 3:00pm
For patients with advanced non-small cell lung cancer who progressed on two or more prior regimens, THIO with Libtayo elicited positive responses.
September 12th 2025, 1:00pm
Dr. Thomas Jankowski explained that THIO, a telomerase inhibitor, is being studied with Libtayo to help overcome resistance in advanced lung cancer.
September 10th 2025, 1:00pm
CURE spoke with Dr. Xiuning Le during the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer.
September 8th 2025, 8:00pm
CURE spoke with Dr. Alexander Spira to learn what patients need to know about the KRAS G12C mutation and its treatment strategies.
September 8th 2025, 7:00pm
In patients with EGFR-mutated NSCLC ivonescimab plus chemotherapy was associated with significant progression-free survival.
September 8th 2025, 4:00pm
Dr. Eric Singhi sat down with CURE to break down the findings from the phase 3 FLAURA2 study, presented at the 2025 IASLC World Conference on Lung Cancer.
September 8th 2025, 1:17pm
Dr. Myung-Ju Ahn shared notable data on ifinatamab deruxtecan for patients with previously treated extensive-stage small cell lung cancer.
September 7th 2025, 6:00pm
People with EGFR+ NSCLC whose disease spread outside the brain after treatment with Tagrisso lived longer when they kept taking Tagrisso along with chemo.
September 7th 2025, 2:00pm
A combination of Iza-bren and Tagrisso showed beneficial results as an initial treatment for advanced/metastatic EGFR-mutated non–small cell lung cancer.
September 6th 2025, 6:00pm
Never-smoker Leah Phillips, co-founder of the Young Lung Cancer Initiative, raises awareness that anyone with lungs can develop lung cancer.
Becoming Cancer-Aware: How My Diagnosis Changed the Way My Family Sees Everyday Products
What Are My Options for Liver Cancer Treatment?
Understanding Clinical Trial Site Supply and Access
When Your Profession Is Your Calling and Redemption